Clinical Report: EYP-1901 Shows Durable, Sustained Efficacy in VERONA
Overview
The VERONA phase 2 trial demonstrated that EYP-1901 significantly outperformed aflibercept in maintaining visual acuity and reducing the need for supplemental anti-VEGF injections in patients with center-involved diabetic macular edema (DME). EYP-1901 showed a favorable safety profile and sustained drug delivery over six months.
Background
Diabetic macular edema (DME) is a leading cause of vision loss in diabetic patients, making effective treatment essential. Current first-line therapies include intravitreal anti-VEGF agents, which require frequent injections. The development of sustained-release therapies like EYP-1901 aims to reduce treatment burden while maintaining efficacy.
Data Highlights
| Arm | Supplement Free Rate at Week 24 | Mean BCVA Improvement | Mean CST Reduction |
|---|---|---|---|
| High Dose EYP-1901 | 73% | 10 lines | Significant |
| Low Dose EYP-1901 | 60% | 3-4 letters | Significant |
| Aflibercept | 50% | 7 letters | Not specified |
Key Findings
- EYP-1901 demonstrated a higher proportion of patients supplement-free at week 24 (73% high dose, 60% low dose) compared to aflibercept (50%).
- Significant improvement in best-corrected visual acuity (BCVA) was observed as early as week 4, with sustained gains through week 24.
- Reduction in central subfield thickness (CST) was noted, favoring the high dose of EYP-1901.
- No serious adverse events related to EYP-1901 were reported, indicating a favorable safety profile.
- 40-50% of patients in the EYP-1901 arms were free of DME at week 24, compared to 0% in the aflibercept arm.
Clinical Implications
The results from the VERONA trial suggest that EYP-1901 could provide a more durable treatment option for patients with DME, potentially reducing the frequency of injections required. Clinicians may consider EYP-1901 as a viable alternative to traditional anti-VEGF therapies, particularly for patients struggling with treatment adherence.
Conclusion
The VERONA phase 2 trial indicates that EYP-1901 offers significant advantages in the management of DME, with durable efficacy and a favorable safety profile. Further studies are anticipated to confirm these findings in larger populations.
References
- Carl Regillo, MD, Retinal Physician, 2025 -- EYP-1901 Shows Durable, Sustained Efficacy in VERONA
- Retinal Physician, 2025 -- EYP-1901 Shows 9-Month Disease Control in NPDR Patients
- Retinal Physician, 2025 -- How Vorolanib Could Shift the DME Landscape
- Diabetic Retinopathy Preferred Practice Pattern® - PubMed
- Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON Trial - ScienceDirect
- retinal physician — EYP-1901 Shows 9-Month Disease Control in NPDR Patients
- Retinal Physician — EYP-1901 Shows 9-Month Disease Control in NPDR Patients
- New Retinal Physician — EyePoint Presents EYP-1901 Data for Wet AMD
- Diabetic Retinopathy Preferred Practice Pattern® - PubMed
- Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON Trial - ScienceDirect
- EYP-1901 Shows Durable, Sustained Efficacy in VERONA | Retinal Physician
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.